Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of HB0025 in advanced endometrial cancer
CTR20230223Phase 2Active
- Sponsor
- Huabo Biopharm
- Start
- Oct 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotiburafusp alfa in endometrial cancer (EC), sponsored by Huabo Biopharm. Primary endpoint: Objective response rate. Started Oct 2023; status: active.
02
Drugs
sotiburafusp alfa
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20230223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230223.